Laboratorio Clinico Avanzado Emmanuel, Inc

CLIA Laboratory Citation Details

2
Total Citations
8
Total Deficiencyies
8
Unique D-Tags
CMS Certification Number 40D0684519
Address Calle Palmer #58, Toa Alta, PR, 00953
City Toa Alta
State PR
Zip Code00953
Phone(787) 705-5858

Citation History (2 surveys)

Survey - December 26, 2019

Survey Type: Standard

Survey Event ID: WQAX11

Deficiency Tags: D5024 D6076 D5405

Summary:

Summary Statement of Deficiencies D5024 HEMATOLOGY CFR(s): 493.1215 If the laboratory provides services in the specialty of Hematology, the laboratory must meet the requirements specified in 493.1230 through 493.1256, 493.1269, and 493. 1281 through 493.1299. This CONDITION is not met as evidenced by: Based on hematology quality control records review ( year 2018-2019) and laboratory director interview at 9:50 A.M. on December 26, 2019, it was determined that the laboratory failed to ensure compliance with the analytic system requirements for hematology. The finding includes: 1. The laboratory failed to follow manufacturer's instructions when patient specimens were tested for (CBC) Complete Blood Count by the Coulter Act 5 diff hematology system. Refer to D5405. D5405 PROCEDURE MANUAL CFR(s): 493.1251(c) Manufacturer's test system instructions or operator manuals may be used, when applicable, to meet the requirements of paragraphs (b)(1) through (b)(12) of this section. Any of the items under paragraphs (b)(1) through (b)(12) of this section not provided by the manufacturer must be provided by the laboratory. This STANDARD is not met as evidenced by: Based on manufacturer's instructions, hematology quality control records review ( years 2018-2019 ) and laboratory director interview at 9:50 a.m. on December 27, 2019, it was determined that the laboratory failed to follow manufacturer's instructions when patient specimens were tested for (CBC) Complete Blood Count by the Coulter Act 5 diff hematology system. The findings include: 1. The laboratory uses Coulter Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Act 5 diff to perform hematology patient tests. 2. The manufacturer establishes that three levels of control material (low, normal and high) must be included each day of testing. 3. Review of hematology quality control records from January 2018 to December 26, 2019, showed that the laboratory did not include the three levels of controls from May 6, 2018 to May 17, 2018. 4. The laboratory processed and reported 149 Complete Blood Count patient's samples those days. 5. The laboratory director confirmed that the laboratory failed to follow manufacturer's instructions when patient specimens were tested for (CBC) Complete Blood Count by the Coulter Act 5 diff hematology system. D6076 LABORATORY DIRECTOR CFR(s): 493.1441 The laboratory must have a director who meets the qualification requirements of 493. 1443 of this subpart and provides overall management and direction in accordance with 493.1445 of this subpart. This CONDITION is not met as evidenced by: Based on hematology quality control records review ( 2018-2019) and interview with the laboratory director on December 16, 2019 at 11:00 A.M., it was determined that the laboratory director failed to fulfill his responsibilities and duties to ensure compliance with the laboratory analytical system requirements for hematology. The finding includes: 1. The laboratory director failed to ensure compliance with the hematology requirements. Refer to D6093. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - February 27, 2018

Survey Type: Standard

Survey Event ID: TUME11

Deficiency Tags: D5451 D6093 D6094 D5791 D6177

Summary:

Summary Statement of Deficiencies D5451 CONTROL PROCEDURES CFR(s): 493.1256(d)(3)(iii)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- At least once a day patient specimens are assayed or examined perform the following for-- Test procedures producing graded or titered results include a negative control material and a control material with graded or titered reactivity, respectively; 493.1256 (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on syphilis serology quality control and patient records review from January 4, 2016 to February 27, 2018 and interview with the laboratory director on February 27, 2018 at 11:15 AM, it was determined that the laboratory did not include a control material with tittered reactivity when the laboratory processed and reported patients with tittered results. The findings include: 1. The laboratory processed syphilis serology patient tests by VDRL (Venereal Disease Research Laboratory) method. 2. Review of quality control and patient log book records showed that from January 4, 2016 to February 28, 2018 the laboratory reported the following patients with tittered test results: Patient # Date Result P2016-322 July 05, 2016 R 1:2 dils P2016-324 July 05, 2016 R 1:2 dils P2016-325 July 05, 2016 R 1:4 dils 2016-711 September 20, 2016 R 1:1 dils 2016-712 September 20, 2016 R 1:1 dils 2016-713 September 20, 2016 R 1: 1 dils 2016-A072 December 22, 2016 R 1:1 dils 2016-A073 December 22, 2016 R 1:2 dils 2016-A074 December 22, 2016 R 1:1 dils 2017-322 April 10, 2017 R 1:2 dils 2017-323 April 10, 2017 R 1:1 dils 2017-325 April 10, 2017 R 1:1 dils 2017-A071 December 19, 2017 R 1:1 dils 2017-A073 December 19, 2017 R 1:2 dils 2017-A075 December 19, 2017 R 1:1 dils 3. The laboratory did not include a tittered quality control material when patient tests were performed. 4. The laboratory director confirmed on February 27, 2018, that the titled control material was not included. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- D5791 ANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1289(a)(c) (a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and when indicated, correct problems identified in the analytic systems specified in 493.1251 through 493.1283. (c) The laboratory must document all analytic systems assessment activities. This STANDARD is not met as evidenced by: Based on quality assessment (QA) records review and laboratory director interview on February 27, 2018 at 11:42 AM, it was determined that the laboratory failed to follow the established Quality Assessment Program to monitor and evaluate the requirement for analytic systems. The findings include: 1. Review of the laboratory quality assessment manual showed that for each analytic process a log sheet was designate to keep track of the laboratory performance. 2. The laboratory did not evaluate aspects regarding the analytic systems: a. that the laboratory did not include a control material with tittered reactivity when the laboratory processed and reported patients with tittered results. Refer to D5451. D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality control programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on quality control records review and laboratory director and testing personnel interview on February 27, 2018 at 11:45 AM, it was determined that laboratory director failed to ensure compliance with the requirements for analytic systems. The finding includes: 1. The laboratory director did not assure that the laboratory: a. included a control material with tittered reactivity when the laboratory processed and reported patients with tittered results. Refer to D5451. D6094 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality assessment programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on Quality Assessment (QA) records review and laboratory director interview on February 27, 2018 at 11:48 AM, it was determined that laboratory failed to ensure compliance with quality assessment (QA) requierements. The finding includes: 1. The laboratory did not evaluate the established Quality Asessment Program to monitor and evaluate the requirement for analytic systems (that the laboratory did not include a control material with tittered reactivity when the laboratory processed and reported patients with tittered results). Refer to D5791. -- 2 of 3 -- D6177 TESTING PERSONNEL RESPONSIBILITIES CFR(s): 493.1495(b)(3) Each individual performing high complexity testing must adhere to the laboratory's quality control policies, document all quality control activities, instrument and procedural calibrations and maintenance performed. This STANDARD is not met as evidenced by: Based on syphilis serology quality control records review and laboratory director interview on February 27, 2018 at 11:48 AM, it was determined that testing personnel failed to follow quality control procedures. The finding includes: 1. The laboratory testing personnel did not include a control material with tittered reactivity when the laboratory processed and reported patients with tittered results. Refer to D5451. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access